Genetic variants of peroxisome proliferator-activated receptor δ are associated with gastric cancer

Digestive Diseases and Sciences

Volumn 58, Issue 10, 2013, Pages 2881-2886

  Jeon, Christie ^a,b   Chang, Shen Chih ^b   Mu, Lina ^c   Zhao, Jinkou ^d   Rao, Jian Yu ^b,e   Lu, Qing Yi ^f   Zhang, Zuo Feng ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gastric cancer; Gene environment interaction; Peroxisome proliferator activated receptors; Salt

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA;

ADULT; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CHINA; CONTROLLED STUDY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HELICOBACTER INFECTION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEAT; PRIORITY JOURNAL; SALT INTAKE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; STOMACH CANCER; STOMACH CARCINOGENESIS;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHINA; FEMALE; GENETIC VARIATION; GENOTYPE; HELICOBACTER INFECTIONS; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR DELTA; PPAR GAMMA; RISK FACTORS; SMOKING; SODIUM CHLORIDE, DIETARY; STOMACH NEOPLASMS;

EID: 84885296261     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-013-2770-2     Document Type: Article

References (24)

1. GLOBOCAN 2008 v2.0. Cancer incidence and mortality worldwide [database on the Internet]. International Agency for Research on Cancer. 2010. Available from: http://globocan.iarc.fr. Accessed 10 May 2013.
2. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132:1133-1145.
3. Terry MB, Gaudet MM, Gammon MD. The epidemiology of gastric cancer. Semin Radiat Oncol. 2002;12:111-127.
4. Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. Nature. 1998;392:402-405.
5. Youssef J, Badr M. Peroxisome proliferator-activated receptors and cancer: challenges and opportunities. Br J Pharmacol. 2011;164:68-82.
6. Peters JM, Gonzalez FJ. Sorting out the functional role(s) of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in cell proliferation and cancer. Biochim Biophys Acta. 2009;1796:230-241.
7. Girroir EE, Hollingshead HE, He P, Zhu B, Perdew GH, Peters JM. Quantitative expression patterns of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) protein in mice. Biochem Biophys Res Commun. 2008;371:456-461.
8. Prasad KN, Saxena A, Ghoshal UC, Bhagat MR, Krishnani N. Analysis of Pro12Ala PPAR gamma polymorphism and Helicobacter pylori infection in gastric adenocarcinoma and peptic ulcer disease. Ann Oncol. 2008;19:1299-1303.
9. Tahara T, Arisawa T, Shibata T, et al. Influence of peroxisome proliferator-activated receptor (PPAR) gamma Plo12Ala polymorphism as a shared risk marker for both gastric cancer and impaired fasting glucose (IFG) in Japanese. Dig Dis Sci. 2008;53:614-621.
10. Larsson SC, Orsini N, Wolk A. Processed meat consumption and stomach cancer risk: a meta-analysis. J Natl Cancer Inst. 2006;98:1078-1087.
11. Villegas R, Yang G, Liu D, et al. Validity and reproducibility of the food-frequency questionnaire used in the Shanghai men's health study. Br J Nutr. 2007;97:993-1000.
12. Shu XO, Yang G, Jin F, et al. Validity and reproducibility of the food frequency questionnaire used in the Shanghai Women's Health Study. Eur J Clin Nutr. 2004;58:17-23.
13. Colmers IN, Bowker SL, Johnson JA. Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab. 2012;38:475-484.
14. Wu CW, Yu J, Sung JJ. Peroxisome proliferator-activated receptor delta and gastric cancer (review). Oncol Rep. 2009;22:451-457.
15. Shan W, Nicol CJ, Ito S, et al. Peroxisome proliferator-activated receptor-beta/delta protects against chemically induced liver toxicity in mice. Hepatology. 2008;47:225-235.
16. Harman FS, Nicol CJ, Marin HE, Ward JM, Gonzalez FJ, Peters JM. Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat Med. 2004;10:481-483.
17. Reed KR, Sansom OJ, Hayes AJ, et al. PPARdelta status and Apc-mediated tumourigenesis in the mouse intestine. Oncogene. 2004;23:8992-8996.
18. Barak Y, Liao D, He W, et al. Effects of peroxisome proliferator- activated receptor delta on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci USA. 2002;99:303-308.
19. Gupta RA, Wang D, Katkuri S, Wang H, Dey SK, DuBois RN. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Nat Med. 2004;10:245-247.
20. Wang XQ, Terry PD, Yan H. Review of salt consumption and stomach cancer risk: epidemiological and biological evidence. World J Gastroenterol. 2009;15:2204-2213.
21. Kumar AP, Quake AL, Chang MK, et al. Repression of NHE1 expression by PPAR gamma activation is a potential new approach for specific inhibition of the growth of tumor cells in vitro and in vivo. Cancer Res. 2009;69:8636-8644.
22. Fais S, De Milito A, You H, Qin W. Targeting vacuolar H+ ATPases as a new strategy against cancer. Cancer Res. 2007;67:10627-10630.
23. Cavaleiro-Pinto M, Peleteiro B, Lunet N, Barros H. Helicobacter pylori infection and gastric cardia cancer: systematic review and meta-analysis. Cancer Causes Control. 2011;22:375-387.
24. Camorlinga-Ponce M, Flores-Luna L, Lazcano-Ponce E, et al. Age and severity of mucosal lesions influence the performance of serologic markers in Helicobacter pylori-associated gastroduodenal pathologies. Cancer Epidemiol Biomarkers Prev. 2008;17:2498-2504.